Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRA Biofrontera	$2.60	$2.95	$2.09 ▼ $7.54	$73.73M	1.02	27,512 shs	7,263 shs
EVFM Evofem Biosciences	$0.01 +4.3%	$0.01	$0.01 ▼ $0.02	$1.16M	-1.01	444,554 shs	700,495 shs
KALA KALA BIO	$4.76 +3.0%	$3.91	$2.92 ▼ $11.20	$29.81M	-1.98	46,421 shs	39,123 shs
MCRB Seres Therapeutics	$11.11 +22.1%	$8.12	$6.53 ▼ $30.60	$79.46M	2.63	134,399 shs	370,870 shs
SLGL Sol-Gel Technologies	$7.40 +1.1%	$7.38	$3.34 ▼ $16.50	$20.39M	1.1	32,957 shs	1,146 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRA Biofrontera	0.00%	0.00%	0.00%	0.00%	0.00%
EVFM Evofem Biosciences	0.00%	-3.09%	-6.00%	+6.82%	-10.48%
KALA KALA BIO	0.00%	+14.36%	+25.89%	-19.37%	-34.84%
MCRB Seres Therapeutics	0.00%	+22.97%	+26.04%	-35.01%	-37.14%
SLGL Sol-Gel Technologies	0.00%	-1.48%	-0.27%	+33.58%	-17.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFRA Biofrontera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	0.5527 of 5 stars	0.0	3.0	0.0	4.8	0.0	0.0	0.0
KALA KALA BIO	3.5099 of 5 stars	3.5	1.0	0.0	4.4	1.0	0.8	0.6
MCRB Seres Therapeutics	3.5872 of 5 stars	2.9	2.0	0.0	4.6	3.3	0.8	0.0
SLGL Sol-Gel Technologies	2.6507 of 5 stars	3.5	3.0	0.0	0.0	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRA Biofrontera	0.00	N/A	N/A	N/A
EVFM Evofem Biosciences	0.00	N/A	N/A	N/A
KALA KALA BIO	3.00	Buy	$13.50	183.61% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	563.07% Upside
SLGL Sol-Gel Technologies	3.00	Buy	$40.00	440.54% Upside

Current Analyst Ratings Breakdown

Latest BFRA, KALA, SLGL, MCRB, and EVFM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
4/4/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRA Biofrontera	$36.19M	2.04	N/A	N/A	$0.35 per share	7.43
EVFM Evofem Biosciences	$11.39M	0.10	N/A	N/A	($2.64) per share	0.00
KALA KALA BIO	$3.89M	7.89	N/A	N/A	$2.02 per share	2.36
MCRB Seres Therapeutics	$126.32M	0.77	N/A	N/A	$1.61 per share	6.90
SLGL Sol-Gel Technologies	$11.54M	1.79	N/A	N/A	$10.36 per share	0.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRA Biofrontera	-$14.88M	-$0.73	N/A	∞	N/A	-59.44%	-93.31%	-24.02%	N/A
EVFM Evofem Biosciences	$52.98M	-$0.05	N/A	∞	N/A	-46.42%	-91.97%	-61.93%	N/A
KALA KALA BIO	-$38.51M	-$8.24	N/A	N/A	N/A	N/A	-369.29%	-64.99%	8/5/2025 (Estimated)
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-41,084.76%	-55.87%	8/12/2025 (Estimated)
SLGL Sol-Gel Technologies	-$10.58M	-$4.70	N/A	N/A	N/A	-107.78%	-43.98%	-35.28%	8/15/2025 (Estimated)

Latest BFRA, KALA, SLGL, MCRB, and EVFM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/23/2025	Q1 2025	SLGL Sol-Gel Technologies	N/A	-$3.20	N/A	-$3.20	N/A	$1.03 million
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRA Biofrontera	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRA Biofrontera	0.13	1.26	1.13
EVFM Evofem Biosciences	N/A	0.11	0.09
KALA KALA BIO	3.19	1.99	1.99
MCRB Seres Therapeutics	N/A	2.11	2.11
SLGL Sol-Gel Technologies	N/A	5.12	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRA Biofrontera	60.07%
EVFM Evofem Biosciences	0.22%
KALA KALA BIO	24.61%
MCRB Seres Therapeutics	59.34%
SLGL Sol-Gel Technologies	26.18%

Insider Ownership

Company	Insider Ownership
BFRA Biofrontera	N/A
EVFM Evofem Biosciences	0.21%
KALA KALA BIO	8.32%
MCRB Seres Therapeutics	4.70%
SLGL Sol-Gel Technologies	66.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRA Biofrontera	138	28.36 million	N/A	Not Optionable
EVFM Evofem Biosciences	120	118.66 million	113.12 million	Not Optionable
KALA KALA BIO	30	6.45 million	5.92 million	Not Optionable
MCRB Seres Therapeutics	330	8.73 million	8.32 million	Optionable
SLGL Sol-Gel Technologies	50	2.79 million	933,000	Optionable

BFRA, KALA, SLGL, MCRB, and EVFM Headlines

Recent News About These Companies

SLGL Sol-Gel Technologies Ltd. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Sol-Gel Technologies Ltd

June 21, 2025 | morningstar.comM

Sol Gel Tech Stock Price History

June 1, 2025 | investing.com

Sol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2025 Results

May 23, 2025 | finanznachrichten.de

Sol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays Pessimistic

May 23, 2025 | msn.com

Sol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D Expenses

May 23, 2025 | quiverquant.comQ

Sol-Gel Reports First Quarter 2025 Results

May 23, 2025 | globenewswire.com

Insider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of Shares

May 3, 2025 | uk.finance.yahoo.com

This Sol-Gel Technologies Insider Increased Their Holding In The Last Year

May 2, 2025 | finance.yahoo.com

Sol-Gel Announces Reverse Share Split

May 1, 2025 | globenewswire.com

Sol-Gel, Mayne Pharma enter product purchase agreement

April 17, 2025 | markets.businessinsider.com

Sol-Gel Technologies Ltd.: Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S.

April 17, 2025 | finanznachrichten.de

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

April 17, 2025 | globenewswire.com

Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis

April 7, 2025 | globenewswire.com

Sol-Gel Technologies Approves Reverse Share Split and Compensation Policy Renewal

April 1, 2025 | tipranks.com

SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know

February 25, 2025 | zacks.com

Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?

February 7, 2025 | finance.yahoo.com

Sol Gel Technologies Ltd (SLGL) Stock Trading Recap

December 26, 2024 | bovnews.comB

Is SolGel Technologies (SLGL) a Great Value Stock Right Now?

December 25, 2024 | zacks.com

Sol-Gel Technologies Reports Strong Q3 2024 Results

November 21, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRA, KALA, SLGL, MCRB, and EVFM Company Descriptions

Biofrontera NASDAQ:BFRA

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Evofem Biosciences NASDAQ:EVFM

$0.0098 +0.00 (+4.26%)

As of 03:49 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

KALA BIO NASDAQ:KALA

$4.76 +0.14 (+3.03%)

As of 04:00 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Seres Therapeutics NASDAQ:MCRB

$11.11 +2.01 (+22.09%)

As of 04:00 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Sol-Gel Technologies NASDAQ:SLGL

$7.40 +0.08 (+1.09%)

As of 02:34 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time